3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
23
Prostatic Neoplasms
8
Carcinoma, Intraductal, Noninfiltrating
3
Thyroid Nodule
2
Stomach Neoplasms
2
Pleural Effusion, Malignant
2
Mouth Neoplasms
2
Fibrosis
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Uterine Hemorrhage
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thromboembolism
1
Stomatitis
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Sarcoma, Endometrial Stromal
1
Risk Malignant Index
1
Renal Insufficiency, Chronic
1
Rectal Neoplasms
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neurofibrosarcoma
1
Neurofibromatosis 1
1
Neoplasms
1
Melanoma
1
Lymphedema
1
Interventions
pazopanib
1
Tomography, X-Ray Computed
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
High-Energy Shock Waves
1
Breathing Exercises
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Coronary Artery Disease
×
High-Energy Shock Waves
×
Clear all
NCT01230905
2017-04-24
AST
Ottawa Heart Institute Research Corporation
Phase 4
Completed
181 enrolled